CA2694504C - (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof - Google Patents

(2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof Download PDF

Info

Publication number
CA2694504C
CA2694504C CA2694504A CA2694504A CA2694504C CA 2694504 C CA2694504 C CA 2694504C CA 2694504 A CA2694504 A CA 2694504A CA 2694504 A CA2694504 A CA 2694504A CA 2694504 C CA2694504 C CA 2694504C
Authority
CA
Canada
Prior art keywords
azabicyclo
pyridinyl
methyl
oct
benzofuran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2694504A
Other languages
English (en)
French (fr)
Other versions
CA2694504A1 (en
Inventor
Merouane Bencherif
Lisa Benson
Gary Maurice Dull
Nikolai Fedorov
Gregory J. Gatto
John Genus
Kristen G. Jordan
Jacob Mathew
Anatoly A. Mazurov
Lan Miao
Julio A. Munoz
Inigo Pfeiffer
Sondra Pfeiffer
Teresa Y. Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gyre Therapeutics Inc
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39945177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2694504(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of CA2694504A1 publication Critical patent/CA2694504A1/en
Application granted granted Critical
Publication of CA2694504C publication Critical patent/CA2694504C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2694504A 2007-08-02 2008-08-01 (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof Expired - Fee Related CA2694504C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US95361307P 2007-08-02 2007-08-02
US95361407P 2007-08-02 2007-08-02
US95361007P 2007-08-02 2007-08-02
US60/953,614 2007-08-02
US60/953,610 2007-08-02
US60/953,613 2007-08-02
US97165407P 2007-09-12 2007-09-12
US60/971,654 2007-09-12
PCT/US2008/071872 WO2009018505A1 (en) 2007-08-02 2008-08-01 (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof

Publications (2)

Publication Number Publication Date
CA2694504A1 CA2694504A1 (en) 2009-02-05
CA2694504C true CA2694504C (en) 2014-01-07

Family

ID=39945177

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2694504A Expired - Fee Related CA2694504C (en) 2007-08-02 2008-08-01 (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof
CA2694510A Abandoned CA2694510A1 (en) 2007-08-02 2008-08-01 Treatment with .alpha.7-selective ligands

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2694510A Abandoned CA2694510A1 (en) 2007-08-02 2008-08-01 Treatment with .alpha.7-selective ligands

Country Status (35)

Country Link
US (6) US20110124678A1 (enExample)
EP (6) EP2182949B1 (enExample)
JP (4) JP2010535252A (enExample)
KR (2) KR20100051684A (enExample)
CN (4) CN101784273B (enExample)
AR (1) AR067775A1 (enExample)
AU (3) AU2008283813A1 (enExample)
BR (2) BRPI0814889A2 (enExample)
CA (2) CA2694504C (enExample)
CL (3) CL2008002271A1 (enExample)
CO (2) CO6260080A2 (enExample)
CY (1) CY1113561T1 (enExample)
DK (2) DK2431037T3 (enExample)
EC (2) ECSP10010007A (enExample)
ES (3) ES2611139T3 (enExample)
HR (1) HRP20130286T1 (enExample)
HU (1) HUE030387T2 (enExample)
IL (1) IL218976A0 (enExample)
ME (1) ME01508B (enExample)
MX (3) MX346451B (enExample)
MY (1) MY148002A (enExample)
NO (2) NO20100078L (enExample)
NZ (2) NZ582828A (enExample)
PE (3) PE20090566A1 (enExample)
PH (2) PH12012501514A1 (enExample)
PL (1) PL2182949T3 (enExample)
PT (1) PT2182949E (enExample)
RS (1) RS52743B (enExample)
RU (2) RU2012140148A (enExample)
SA (2) SA08290475B1 (enExample)
SI (1) SI2182949T1 (enExample)
TW (3) TW201402116A (enExample)
UY (1) UY31265A (enExample)
WO (2) WO2009018511A2 (enExample)
ZA (1) ZA201000719B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US20110098312A1 (en) * 2008-05-12 2011-04-28 Targacept ,Inc Methods for preventing the development of retinopathy by the oral administration of nnr ligands
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
ES2570657T3 (es) 2010-05-17 2016-05-19 Forum Pharmaceuticals Inc Una forma cristalina de hidrocloruro de (R)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidrato
CA2808797A1 (en) * 2010-07-26 2012-02-02 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors
MX2013003344A (es) 2010-09-23 2013-06-28 Abbvie Inc Monohidrato de un derivado de azaadamantano.
PH12013501509A1 (en) * 2011-01-18 2019-08-07 Targacept Inc Treatment of cognitive dysfunction in schizophrenia
AU2012210652B2 (en) 2011-01-27 2016-04-07 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
KR20140018286A (ko) 2011-03-18 2014-02-12 노파르티스 아게 파킨슨병에서의 도파민 유발 이상운동증에서 사용하기 위한 알파 7 니코틴성 아세틸콜린 수용체 활성화제 및 mGluR5 길항제의 조합물
PL2685979T3 (pl) 2011-03-18 2017-02-28 Alkermes Pharma Ireland Limited Kompozycje farmaceutyczne do wstrzykiwania zawierające środek nierozpuszczalny w wodzie, środek przeciwpsychotyczny, laurynian sorbitanu i polisorbat 20
WO2012129262A1 (en) 2011-03-23 2012-09-27 Targacept, Inc. Treatment of attention deficit/hyperactivity disease
US20140128606A1 (en) 2011-06-30 2014-05-08 Toray Industries, Inc. Antipruritic agent
TW201311698A (zh) * 2011-08-22 2013-03-16 Targacept Inc 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷
CA2852268C (en) 2011-10-20 2020-08-25 Novartis Ag Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
EP2827868B8 (en) 2012-03-19 2019-12-18 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
NZ630703A (en) * 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising glycerol esters
WO2013169646A1 (en) 2012-05-08 2013-11-14 Envivo Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
NZ631345A (en) 2012-09-19 2017-06-30 Alkermes Pharma Ireland Ltd Pharmaceutical compositions having improved storage stability
ES2661050T3 (es) 2012-12-11 2018-03-27 Novartis Ag Biomarcador predictivo de la capacidad de respuesta a tratamiento con activador del receptor nicotínico de acetilcolina alfa-7
CA2898043C (en) 2013-01-15 2019-08-06 Novartis Ag Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
US20150313884A1 (en) 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
CN105263495B (zh) 2013-01-15 2019-05-14 诺华有限公司 α7烟碱型乙酰胆碱受体激动剂的应用
CA2898045C (en) 2013-01-15 2018-08-28 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
WO2014153424A1 (en) * 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
JP6524110B2 (ja) 2014-03-20 2019-06-05 アルカームス ファーマ アイルランド リミテッド 注射速度が増大したアリピプラゾール調合物
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
CN104288771B (zh) * 2014-09-30 2017-03-15 郑州大学第五附属医院 α7nAChR激动剂的新用途
CA2983927A1 (en) 2015-05-06 2016-11-10 The Regents Of The University Of California K-ras modulators
US9724340B2 (en) * 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
US10282666B1 (en) 2015-11-10 2019-05-07 Google Llc Coherency detection and information management system
RU2675111C2 (ru) * 2017-03-31 2018-12-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" Способ стимуляции нейрогенеза в гиппокампе
EP3612526A2 (en) 2017-04-20 2020-02-26 The Regents of the University of California K-ras modulators
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203990A (en) 1979-04-30 1980-05-20 G. D. Searle & Co. Anti-diarrheal 2-substituted quinuclidines
DE58906678D1 (de) 1988-07-28 1994-02-24 Ciba Geigy Kupfer- und Nickeldihalogenidkomplexe, Verfahren zu deren Herstellung und deren Verwendung.
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
EP0402056A3 (en) 1989-06-06 1991-09-04 Beecham Group p.l.c. Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them
CA2022886A1 (en) 1989-08-08 1991-02-09 Raymond Baker Substituted pyridines, their preparation, formulations and use in dementia
IN173570B (enExample) 1989-11-23 1994-06-04 Pfizer
DK40890D0 (da) 1990-02-16 1990-02-16 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
EP0492903A1 (en) 1990-12-21 1992-07-01 MERCK SHARP & DOHME LTD. Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma
JP2657583B2 (ja) 1991-03-01 1997-09-24 ユニバーシテイ オブ フロリダ リサーチ ファンデーション インコーポレイテッド 神経系変性疾患の治療に対するニコチン類似体の利用
US5212188A (en) 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5276043A (en) 1992-04-10 1994-01-04 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5977144A (en) 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
DE69332641T2 (de) * 1992-08-31 2003-11-27 University Of Florida Research Foundation, Inc. Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
IL109451A0 (en) * 1993-04-29 1994-07-31 Zeneca Ltd Heterocyclic derivatives
WO1995003306A1 (en) 1993-07-22 1995-02-02 E.I. Du Pont De Nemours And Company Arthropodicidal azacyclic heterocycles
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5510355A (en) 1994-09-06 1996-04-23 Bencherif; Merouane Depolarizing skeletal muscle relaxants
US5998404A (en) 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5616707A (en) 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5824692A (en) 1995-01-06 1998-10-20 Lippiello; Patrick Michael Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
JPH11500113A (ja) 1995-02-17 1999-01-06 ノボ ノルディスク アクティーゼルスカブ ヘテロ環化合物類の使用
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
AU6299396A (en) 1995-06-29 1997-01-30 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
AU7083596A (en) 1995-09-22 1997-04-09 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
US5712270A (en) 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
US5811442A (en) 1997-02-21 1998-09-22 Bencherif; Merouane Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
TR199902942T2 (xx) 1997-05-30 2000-04-21 Neurosearch A/S Nikotinik ACh Resept�rlerinde kolinerjik ligandlar olarak 8-Azabisiklo(3.2.1)okt-ene ve okstan t�revleri.
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
PT1068208E (pt) 1998-04-02 2003-09-30 Targacept Inc Derivados do azatriciclo¬3.3.1.1|decano e composicoes farmaceuticas contendo os mesmos
WO1999062505A2 (en) 1998-06-01 1999-12-09 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
US6310043B1 (en) 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
GB9821503D0 (en) 1998-10-02 1998-11-25 Novartis Ag Organic compounds
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6734215B2 (en) 1998-12-16 2004-05-11 University Of South Florida Exo-S-mecamylamine formulation and use in treatment
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
FR2791678B1 (fr) * 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
KR100751981B1 (ko) 2000-06-27 2007-08-28 라보라토리오스 살바트, 에스.에이. 아릴알킬아민으로부터 유도된 카바메이트
WO2002016358A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002016356A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002016357A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
EP1311505A2 (en) 2000-08-21 2003-05-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
EP1345937B1 (en) 2000-12-22 2005-09-28 Almirall Prodesfarma AG Quinuclidine carbamate derivatives and their use as m3 antagonists
US20020086871A1 (en) 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
US6569865B2 (en) * 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
SI1397366T1 (sl) 2001-06-01 2007-06-30 Astrazeneca Ab Nov ligand za nikotinske acetilholinske receptorje, koristen v terapiji
AR036040A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
US7109204B2 (en) 2001-08-01 2006-09-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US20030069296A1 (en) 2001-08-24 2003-04-10 Wishka Donn G. Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease
WO2003018585A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
DE60218493D1 (de) 2001-09-12 2007-04-12 Pharmacia & Upjohn Co Llc Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
US6858613B2 (en) 2002-02-19 2005-02-22 Pfizer Inc. Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
BR0307874A (pt) 2002-02-20 2004-12-28 Upjohn Co Atividade de compostos azabicìclicos com receptor de acetilcolina nicotìnica alfa7
CN1325501C (zh) 2002-04-18 2007-07-11 阿斯特拉曾尼卡有限公司 杂环化合物
KR20040099447A (ko) 2002-04-18 2004-11-26 아스트라제네카 아베 푸릴 화합물
AU2003224545B2 (en) 2002-04-18 2009-08-13 Astrazeneca Ab Thienyl compounds
EP1542999A1 (en) * 2002-08-01 2005-06-22 Pharmacia & Upjohn Company LLC 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
SE0202465D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
EP1905771A3 (en) 2002-08-14 2008-11-26 NeuroSearch A/S Quinuclidine derivatives and their use
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
CA2495248A1 (en) 2002-08-30 2004-03-11 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
KR101129933B1 (ko) 2002-09-25 2012-03-23 메모리 파마슈티칼스 코포레이션 인다졸, 벤조티아졸 및 벤조이소티아졸 및 그의 제조 및용도
WO2004039366A1 (en) 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
WO2004039815A2 (en) 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
DE60317564T2 (de) 2002-12-06 2008-10-23 The Feinstein Institute For Medical Research Hemmung von entzündungen unter verwendung von alpha-7-rezeptor verbindenden cholinergen agonisten
WO2004052348A2 (en) 2002-12-11 2004-06-24 Pharmacia & Upjohn Company Llc Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
EA200500783A1 (ru) 2002-12-11 2005-12-29 ФАРМАЦИЯ ЭНД АПДЖОН КОМПАНИ ЭлЭлСи Комбинация для лечения синдрома дефицита внимания с гиперактивностью
US6917746B2 (en) 2002-12-17 2005-07-12 3M Innovative Properties Company Apparatus and method for creating a fiber optic circuit
US6777617B2 (en) 2002-12-30 2004-08-17 3M Innovative Properties Company Telecommunications terminal
NZ540998A (en) 2003-02-27 2008-06-30 Neurosearch As Novel diazabicyclic aryl derivatives
AU2004255920B2 (en) 2003-07-08 2008-05-15 Astrazeneca Ab Spiro [1-azabicyclo [2.2.2] octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor
EP1668016A1 (en) 2003-09-25 2006-06-14 AstraZeneca AB Ligands
CN100494202C (zh) 2003-10-21 2009-06-03 阿斯利康(瑞典)有限公司 螺呋喃并吡啶芳基衍生物
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050137217A1 (en) 2003-12-22 2005-06-23 Jianguo Ji Spirocyclic quinuclidinic ether derivatives
US20050137203A1 (en) 2003-12-22 2005-06-23 Jianguo Ji 3-quinuclidinyl amino-substituted biaryl derivatives
US7160876B2 (en) 2003-12-22 2007-01-09 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050137398A1 (en) 2003-12-22 2005-06-23 Jianguo Ji 3-Quinuclidinyl heteroatom bridged biaryl derivatives
AU2005210039B2 (en) * 2004-02-04 2010-09-02 Neurosearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
JP2007534692A (ja) 2004-04-22 2007-11-29 メモリー・ファーマシューティカルズ・コーポレイション インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用
WO2005111038A2 (en) 2004-05-07 2005-11-24 Memory Pharmaceuticals Corporation 1h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
EP1805183B1 (en) * 2004-10-20 2010-12-29 NeuroSearch A/S Novel diazabicyclic aryl derivatives and their medical use
US20080113983A1 (en) 2004-12-15 2008-05-15 Astrazeneca Ab Nicotinic Acetylcholine Receptor Ligands
US7625924B2 (en) * 2004-12-22 2009-12-01 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
CA2610795C (en) 2005-06-07 2015-01-06 University Of Florida Research Foundation, Inc. 3-arylidene-anabaseine compounds as alpha 7 nicotitnic receptor selective ligands
ATE482959T1 (de) 2005-08-22 2010-10-15 Targacept Inc Heteroarylsubstituierte diazatricycloalkane, verfahren zu deren herstellung und deren anwendung
JP2009509964A (ja) 2005-09-23 2009-03-12 メモリー・ファーマシューティカルズ・コーポレイション インダゾール類、ベンゾチアゾール類、ベンゾイソオキサゾール類、ピラゾロピリジン類、イソチアゾロピリジン類、およびそれらの製造と用途
US8316104B2 (en) * 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US20110059947A1 (en) * 2008-02-13 2011-03-10 Targacept, Inc. Alpha 7 nicotinic agonists and antipsychotics

Also Published As

Publication number Publication date
ES2611139T3 (es) 2017-05-05
NO20100078L (no) 2010-02-26
US8119659B2 (en) 2012-02-21
JP6106549B2 (ja) 2017-04-05
PE20121820A1 (es) 2013-01-23
JP2013231070A (ja) 2013-11-14
NZ582828A (en) 2011-09-30
AU2008283813A1 (en) 2009-02-05
IL218976A0 (en) 2012-05-31
KR20100051684A (ko) 2010-05-17
AU2008283807A1 (en) 2009-02-05
AU2012203288A1 (en) 2012-06-21
CA2694510A1 (en) 2009-02-05
US20110263859A1 (en) 2011-10-27
US20150045386A1 (en) 2015-02-12
BRPI0814889A2 (pt) 2017-05-23
US8846715B2 (en) 2014-09-30
ECSP10010008A (es) 2010-04-30
CL2013002227A1 (es) 2013-11-08
EP2182949B1 (en) 2013-01-02
MX346451B (es) 2017-03-17
EP2484363A1 (en) 2012-08-08
JP5358573B2 (ja) 2013-12-04
PH12012501514A1 (en) 2014-04-28
HRP20130286T1 (en) 2013-06-30
ZA201000719B (en) 2010-11-24
BRPI0815009A2 (pt) 2015-03-03
EP2182949A1 (en) 2010-05-12
EP2409703A1 (en) 2012-01-25
RU2012140148A (ru) 2014-03-27
TW201402117A (zh) 2014-01-16
EP2465501B1 (en) 2016-10-05
CL2013002226A1 (es) 2013-11-15
SA112330303B1 (ar) 2014-11-10
JP2010535252A (ja) 2010-11-18
DK2431037T3 (en) 2017-02-13
SI2182949T1 (sl) 2013-10-30
US8541446B2 (en) 2013-09-24
TWI429435B (zh) 2014-03-11
CO6260081A2 (es) 2011-03-22
NO20100077L (no) 2010-02-26
US20140024673A1 (en) 2014-01-23
DK2182949T3 (da) 2013-04-02
ME01508B (me) 2014-04-20
TW201402116A (zh) 2014-01-16
WO2009018511A2 (en) 2009-02-05
JP5852611B2 (ja) 2016-02-03
PT2182949E (pt) 2013-02-14
RS52743B (sr) 2013-08-30
PH12012501513A1 (en) 2014-04-28
AU2008283807B2 (en) 2012-03-29
MX2010001293A (es) 2011-02-25
CY1113561T1 (el) 2016-06-22
CN103172628A (zh) 2013-06-26
EP2431037A1 (en) 2012-03-21
MY148002A (en) 2013-02-28
PE20121821A1 (es) 2013-01-23
WO2009018511A3 (en) 2009-04-23
US7981906B2 (en) 2011-07-19
HUE030387T2 (en) 2017-05-29
HK1140968A1 (en) 2010-10-29
EP2465501A1 (en) 2012-06-20
PE20090566A1 (es) 2009-05-13
CO6260080A2 (es) 2011-03-22
PL2182949T3 (pl) 2013-06-28
CN101784273A (zh) 2010-07-21
UY31265A (es) 2009-12-14
ECSP10010007A (es) 2010-07-30
TW200914004A (en) 2009-04-01
KR20100063043A (ko) 2010-06-10
JP2013231071A (ja) 2013-11-14
EP2431037B1 (en) 2016-11-30
CL2008002271A1 (es) 2008-12-19
US20090048290A1 (en) 2009-02-19
EP2185152A2 (en) 2010-05-19
MX346748B (es) 2017-03-29
RU2012140182A (ru) 2014-03-27
AR067775A1 (es) 2009-10-21
NZ582986A (en) 2012-01-12
ES2606752T3 (es) 2017-03-27
CN101868237A (zh) 2010-10-20
US20120129885A1 (en) 2012-05-24
US20110124678A1 (en) 2011-05-26
CA2694504A1 (en) 2009-02-05
SA08290475B1 (ar) 2013-06-22
ES2415107T3 (es) 2013-07-24
CN106831755A (zh) 2017-06-13
JP2010535251A (ja) 2010-11-18
AU2012203288B2 (en) 2013-08-29
CN101784273B (zh) 2017-01-18
WO2009018505A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
CA2694504C (en) (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof
US20110257224A1 (en) Preparation and therapeutic applications of (2s,3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
RU2476220C2 (ru) (2s,3r)-n-(2-((3-пиридинил)метил)-1-азабицикло[2.2.2]окт-3-ил)бензофуран-2-карбоксамид, новые солевые формы и способы их применения
HK1168306A (en) (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof
HK1168306B (en) (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof
HK1140968B (en) (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo [2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof
HK1186469A (en) (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof
HK1164319B (en) Preparation and therapeutic applications of (2s,3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220802